Posted On:
December 11, 2009
Postmarket Survillance of Drugs
The FDA Law Blog reports on "Postmarket Safety Oversight Improvement; Seeks Timeline for Transfer of Certain Protocol Reviews from Office of New Drugs to the Office of Surveillance and Epidemiology." The post cites a GAO report following up on extensive efforts to revamp the postmarket surveillance of drugs by the FDA, something that has become critically necessary, especially in light of repeated abuses by the drug companies in selling and marketing products well after deficiencies come to light.
